Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment Feb 22 Written by Health Wildcatters Health Wildcatters Previous Previous VenoStent raises $2.2 million to begin clinical trials Next Next University of Houston engineers recognized, TMCx company raises funds, and more local innovation news
Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment Feb 22 Written by Health Wildcatters Health Wildcatters
